Ahmed Osman, Karageorgiou John, Kumar Abhishek, Patel Mikin, Jones Joshua, Nezami Nariman
Department of Radiology, University of Chicago Medical Center, Chicago, IL, USA.
Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, MO, USA.
CVIR Endovasc. 2025 May 1;8(1):36. doi: 10.1186/s42155-025-00555-w.
Obsidio Conformable Embolic (Obsidio) is a ready-made hydrogel with unique shear-thinning properties, used for occlusion of blood flow to control bleeding or hemorrhage in the peripheral vasculature and embolization of hypervascular tumors. While pre-clinical and clinical data have demonstrated successful embolizations using Obsidio, clinical experience overall is still limited, prompting a multi-institutional field assessment survey to collect additional data on the clinical utility and procedural details from a variety of Obsidio users. The field survey collected data from 131 embolization procedures performed using Obsidio between May and November 2023 at 27 institutions within the United States. Data collection included embolization site, vessel size, any adjunctive embolics used. The primary objective of the survey was to evaluate technical success, defined as complete embolization of the target vasculature immediately following the index procedure, as confirmed by angiography.
Of the 131 embolization procedures performed, 69% (n = 90) were for hemorrhage control, 15% (n = 19) were for hypervascular tumors, and 17% (n = 22) were for other indications. Embolization of the gastroduodenal artery was the most common indication (n = 19/131; 15%). A single syringe (1 mL) or less of Obsidio was used for most cases (93%). In 33/131 cases (25%), Obsidio was combined with other embolization devices including coils (n = 25; 19%), particle-based embolics (n = 6; 4.6%), or plugs (n = 2; 1.5%). Technical success was achieved in 100% of Obsidio embolization cases (131/131 procedures).
Initial clinical experience demonstrated successful embolization of end-organ bleeds and hypervascular tumors utilizing Obsidio, thus making it an effective embolic agent alone or in conjunction with other embolic devices.
Obsidio适形栓塞剂（Obsidio）是一种预制水凝胶，具有独特的剪切变稀特性，用于阻断血流以控制外周血管系统的出血或大出血以及超血管性肿瘤的栓塞。虽然临床前和临床数据已证明使用Obsidio进行栓塞成功，但总体临床经验仍然有限，这促使开展一项多机构实地评估调查，以从各类Obsidio使用者那里收集有关临床效用和操作细节的更多数据。该实地调查收集了2023年5月至11月期间在美国27家机构使用Obsidio进行的131例栓塞手术的数据。数据收集包括栓塞部位、血管大小、使用的任何辅助栓塞剂。该调查的主要目的是评估技术成功率，技术成功定义为在索引手术之后立即通过血管造影确认目标血管系统完全栓塞。
在进行的131例栓塞手术中，69%（n = 90）用于控制出血，15%（n = 19）用于超血管性肿瘤，17%（n = 22）用于其他适应症。胃十二指肠动脉栓塞是最常见的适应症（n = 19/131；15%）。大多数病例（93%）使用了一支（1 mL）或更少的Obsidio注射器。在33/131例病例（25%）中，Obsidio与其他栓塞装置联合使用，包括线圈（n = 25；19%）、基于颗粒的栓塞剂（n = 6；4.6%）或栓塞塞（n = 2；1.5%）。Obsidio栓塞病例的技术成功率达到100%（131/131例手术）。
初步临床经验表明，利用Obsidio可成功栓塞终末器官出血和超血管性肿瘤，因此它单独使用或与其他栓塞装置联合使用时都是一种有效的栓塞剂。
